Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
Identifieur interne : 000796 ( Pmc/Corpus ); précédent : 000795; suivant : 000797Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
Auteurs : Salam Abbara ; Raphaele Seror ; Julien Henry ; Pascale Chretien ; Aude Gleizes ; Salima Hacein-Bey-Abina ; Xavier Mariette ; Gaetane NocturneSource :
- RMD Open [ 2056-5933 ] ; 2019.
Abstract
To describe and compare the clinical and biological characteristics of subjects with primary Sjögren’s syndrome (pSS) with and without anti-RNP antibodies.
Patients fulfilling the American College of Rheumatology (ACR)/EULAR 2016 criteria for pSS and having anti-RNP antibodies, without other connective tissue disease diagnosed and no anti-dsDNA antibodies were retrieved from the database from our French National Reference Center. These patients were compared with all other patients with pSS with negative anti-Sm, anti-RNP and anti-dsDNA antibodies.
Overall, 21 patients with pSS positive for anti-RNP antibodies and 446 negative for anti-RNP antibodies were retrieved. Anti-RNP-positive patients had a lower median age at onset of pSS symptoms (41.0 vs 50.0 years, p=0.01), a higher median EULAR Sjögren’s syndrome disease activity index at inclusion (8.0 vs 3.0, p<0.01), more frequently constitutional symptoms (14.3% vs 0.01%, p<0.01), myositis (19.0% vs 2.3%, p<0.01) and pulmonary (19.0% vs 5.7%, p=0.04) involvement. Moreover, anti-RNP-positive patients had higher median gammaglobulin levels (22.5 vs 13 g/L, p<0.01), more frequently anti-SSA antibodies (90.5% vs 67.1%, p=0.03), but less frequent lymphocytic sialadenitis with a focus score ≥1 (66.7% vs 85.5%, p=0.03). If the analysis is restricted to anti-SSA-positive patients, anti-RNP positivity is associated with the same clinicobiologic features except the pulmonary involvement.
Patients with pSS with anti-RNP antibodies displayed a more active systemic disease, with more frequent muscular and pulmonary involvement, and increased gammaglobulin level, compared with anti-RNP-negative patients.
Url:
DOI: 10.1136/rmdopen-2019-001033
PubMed: 31673417
PubMed Central: 6802987
Links to Exploration step
PMC:6802987Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement</title><author><name sortKey="Abbara, Salam" sort="Abbara, Salam" uniqKey="Abbara S" first="Salam" last="Abbara">Salam Abbara</name><affiliation><nlm:aff id="aff1"><institution>Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Seror, Raphaele" sort="Seror, Raphaele" uniqKey="Seror R" first="Raphaele" last="Seror">Raphaele Seror</name><affiliation><nlm:aff id="aff1"><institution>Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff2"><institution>INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Paris-Sud University</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Henry, Julien" sort="Henry, Julien" uniqKey="Henry J" first="Julien" last="Henry">Julien Henry</name><affiliation><nlm:aff id="aff1"><institution>Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Chretien, Pascale" sort="Chretien, Pascale" uniqKey="Chretien P" first="Pascale" last="Chretien">Pascale Chretien</name><affiliation><nlm:aff id="aff3"><institution content-type="department">Department of Immunology</institution>,<institution>Hôpital Kremlin Bicêtre, Assistance Publique–Hopitaux de Paris (AP-HP)</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Gleizes, Aude" sort="Gleizes, Aude" uniqKey="Gleizes A" first="Aude" last="Gleizes">Aude Gleizes</name><affiliation><nlm:aff id="aff3"><institution content-type="department">Department of Immunology</institution>,<institution>Hôpital Kremlin Bicêtre, Assistance Publique–Hopitaux de Paris (AP-HP)</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff4"><institution>Université Paris-Sud, INSERM UMR 996, Faculty of Pharmacy, Université Paris-Saclay</institution>,<addr-line content-type="city">Châtenay-Malabry</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Hacein Bey Abina, Salima" sort="Hacein Bey Abina, Salima" uniqKey="Hacein Bey Abina S" first="Salima" last="Hacein-Bey-Abina">Salima Hacein-Bey-Abina</name><affiliation><nlm:aff id="aff3"><institution content-type="department">Department of Immunology</institution>,<institution>Hôpital Kremlin Bicêtre, Assistance Publique–Hopitaux de Paris (AP-HP)</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff5"><institution>UTCBS, CNRS UMR 8258, INSERM U1022, Faculté de Pharmacie de Paris, Université Sorbonne-Paris-Cité, Université Paris- Descartes</institution>,<addr-line content-type="city">Paris</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name><affiliation><nlm:aff id="aff1"><institution>Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff2"><institution>INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Paris-Sud University</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Nocturne, Gaetane" sort="Nocturne, Gaetane" uniqKey="Nocturne G" first="Gaetane" last="Nocturne">Gaetane Nocturne</name><affiliation><nlm:aff id="aff1"><institution>Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff2"><institution>INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Paris-Sud University</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31673417</idno><idno type="pmc">6802987</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802987</idno><idno type="RBID">PMC:6802987</idno><idno type="doi">10.1136/rmdopen-2019-001033</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000796</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000796</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement</title><author><name sortKey="Abbara, Salam" sort="Abbara, Salam" uniqKey="Abbara S" first="Salam" last="Abbara">Salam Abbara</name><affiliation><nlm:aff id="aff1"><institution>Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Seror, Raphaele" sort="Seror, Raphaele" uniqKey="Seror R" first="Raphaele" last="Seror">Raphaele Seror</name><affiliation><nlm:aff id="aff1"><institution>Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff2"><institution>INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Paris-Sud University</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Henry, Julien" sort="Henry, Julien" uniqKey="Henry J" first="Julien" last="Henry">Julien Henry</name><affiliation><nlm:aff id="aff1"><institution>Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Chretien, Pascale" sort="Chretien, Pascale" uniqKey="Chretien P" first="Pascale" last="Chretien">Pascale Chretien</name><affiliation><nlm:aff id="aff3"><institution content-type="department">Department of Immunology</institution>,<institution>Hôpital Kremlin Bicêtre, Assistance Publique–Hopitaux de Paris (AP-HP)</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Gleizes, Aude" sort="Gleizes, Aude" uniqKey="Gleizes A" first="Aude" last="Gleizes">Aude Gleizes</name><affiliation><nlm:aff id="aff3"><institution content-type="department">Department of Immunology</institution>,<institution>Hôpital Kremlin Bicêtre, Assistance Publique–Hopitaux de Paris (AP-HP)</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff4"><institution>Université Paris-Sud, INSERM UMR 996, Faculty of Pharmacy, Université Paris-Saclay</institution>,<addr-line content-type="city">Châtenay-Malabry</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Hacein Bey Abina, Salima" sort="Hacein Bey Abina, Salima" uniqKey="Hacein Bey Abina S" first="Salima" last="Hacein-Bey-Abina">Salima Hacein-Bey-Abina</name><affiliation><nlm:aff id="aff3"><institution content-type="department">Department of Immunology</institution>,<institution>Hôpital Kremlin Bicêtre, Assistance Publique–Hopitaux de Paris (AP-HP)</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff5"><institution>UTCBS, CNRS UMR 8258, INSERM U1022, Faculté de Pharmacie de Paris, Université Sorbonne-Paris-Cité, Université Paris- Descartes</institution>,<addr-line content-type="city">Paris</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name><affiliation><nlm:aff id="aff1"><institution>Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff2"><institution>INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Paris-Sud University</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Nocturne, Gaetane" sort="Nocturne, Gaetane" uniqKey="Nocturne G" first="Gaetane" last="Nocturne">Gaetane Nocturne</name><affiliation><nlm:aff id="aff1"><institution>Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff2"><institution>INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Paris-Sud University</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></nlm:aff></affiliation></author></analytic><series><title level="j">RMD Open</title><idno type="eISSN">2056-5933</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objectives</title><p>To describe and compare the clinical and biological characteristics of subjects with primary Sjögren’s syndrome (pSS) with and without anti-RNP antibodies.</p></sec><sec><title>Methods</title><p>Patients fulfilling the American College of Rheumatology (ACR)/EULAR 2016 criteria for pSS and having anti-RNP antibodies, without other connective tissue disease diagnosed and no anti-dsDNA antibodies were retrieved from the database from our French National Reference Center. These patients were compared with all other patients with pSS with negative anti-Sm, anti-RNP and anti-dsDNA antibodies.</p></sec><sec><title>Results</title><p>Overall, 21 patients with pSS positive for anti-RNP antibodies and 446 negative for anti-RNP antibodies were retrieved. Anti-RNP-positive patients had a lower median age at onset of pSS symptoms (41.0 vs 50.0 years, p=0.01), a higher median EULAR Sjögren’s syndrome disease activity index at inclusion (8.0 vs 3.0, p<0.01), more frequently constitutional symptoms (14.3% vs 0.01%, p<0.01), myositis (19.0% vs 2.3%, p<0.01) and pulmonary (19.0% vs 5.7%, p=0.04) involvement. Moreover, anti-RNP-positive patients had higher median gammaglobulin levels (22.5 vs 13 g/L, p<0.01), more frequently anti-SSA antibodies (90.5% vs 67.1%, p=0.03), but less frequent lymphocytic sialadenitis with a focus score ≥1 (66.7% vs 85.5%, p=0.03). If the analysis is restricted to anti-SSA-positive patients, anti-RNP positivity is associated with the same clinicobiologic features except the pulmonary involvement.</p></sec><sec><title>Conclusion</title><p>Patients with pSS with anti-RNP antibodies displayed a more active systemic disease, with more frequent muscular and pulmonary involvement, and increased gammaglobulin level, compared with anti-RNP-negative patients.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Ramos Casals, M" uniqKey="Ramos Casals M">M Ramos-Casals</name></author><author><name sortKey="Brito Zer N, P" uniqKey="Brito Zer N P">P Brito-Zerón</name></author><author><name sortKey="Seror, R" uniqKey="Seror R">R Seror</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shiboski, Ch" uniqKey="Shiboski C">CH Shiboski</name></author><author><name sortKey="Shiboski, Sc" uniqKey="Shiboski S">SC Shiboski</name></author><author><name sortKey="Seror, R" uniqKey="Seror R">R Seror</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Payet, J" uniqKey="Payet J">J Payet</name></author><author><name sortKey="Belkhir, R" uniqKey="Belkhir R">R Belkhir</name></author><author><name sortKey="Gottenberg, Je" uniqKey="Gottenberg J">JE Gottenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cavazzana, I" uniqKey="Cavazzana I">I Cavazzana</name></author><author><name sortKey="Ceribelli, A" uniqKey="Ceribelli A">A Ceribelli</name></author><author><name sortKey="Quinzanini, M" uniqKey="Quinzanini M">M Quinzanini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Benito Garcia, E" uniqKey="Benito Garcia E">E Benito-Garcia</name></author><author><name sortKey="Schur, Ph" uniqKey="Schur P">PH Schur</name></author><author><name sortKey="Lahita, R" uniqKey="Lahita R">R Lahita</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sharp, Gc" uniqKey="Sharp G">GC Sharp</name></author><author><name sortKey="Irvin, Ws" uniqKey="Irvin W">WS Irvin</name></author><author><name sortKey="Tan, Em" uniqKey="Tan E">EM Tan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ter Borg, Ej" uniqKey="Ter Borg E">EJ ter Borg</name></author><author><name sortKey="Groen, H" uniqKey="Groen H">H Groen</name></author><author><name sortKey="Horst, G" uniqKey="Horst G">G Horst</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Petri, M" uniqKey="Petri M">M Petri</name></author><author><name sortKey="Orbai, A M" uniqKey="Orbai A">A-M Orbai</name></author><author><name sortKey="Alarc N, Gs" uniqKey="Alarc N G">GS Alarcón</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chisholm, Dm" uniqKey="Chisholm D">DM Chisholm</name></author><author><name sortKey="Mason, Dk" uniqKey="Mason D">DK Mason</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alarcon Segovia, D" uniqKey="Alarcon Segovia D">D Alarcon-Segovia</name></author><author><name sortKey="Villareal, M" uniqKey="Villareal M">M Villareal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kasukawa, R" uniqKey="Kasukawa R">R Kasukawa</name></author><author><name sortKey="Sharp, G" uniqKey="Sharp G">G Sharp</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bournia, V K" uniqKey="Bournia V">V-K Bournia</name></author><author><name sortKey="Vlachoyiannopoulos, Pg" uniqKey="Vlachoyiannopoulos P">PG Vlachoyiannopoulos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Paradowska Gorycka, A" uniqKey="Paradowska Gorycka A">A Paradowska-Gorycka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karlsen, M" uniqKey="Karlsen M">M Karlsen</name></author><author><name sortKey="Jakobsen, K" uniqKey="Jakobsen K">K Jakobsen</name></author><author><name sortKey="Jonsson, R" uniqKey="Jonsson R">R Jonsson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goules, Av" uniqKey="Goules A">AV Goules</name></author><author><name sortKey="Kapsogeorgou, Ek" uniqKey="Kapsogeorgou E">EK Kapsogeorgou</name></author><author><name sortKey="Tzioufas, Ag" uniqKey="Tzioufas A">AG Tzioufas</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">RMD Open</journal-id><journal-id journal-id-type="iso-abbrev">RMD Open</journal-id><journal-id journal-id-type="hwp">rmdopen</journal-id><journal-id journal-id-type="publisher-id">rmdopen</journal-id><journal-title-group><journal-title>RMD Open</journal-title></journal-title-group><issn pub-type="epub">2056-5933</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31673417</article-id><article-id pub-id-type="pmc">6802987</article-id><article-id pub-id-type="publisher-id">rmdopen-2019-001033</article-id><article-id pub-id-type="doi">10.1136/rmdopen-2019-001033</article-id><article-categories><subj-group subj-group-type="heading"><subject>Sjögren Syndrome</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group><series-title>Original article</series-title></article-categories><title-group><article-title>Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement</article-title></title-group><contrib-group><contrib id="author-70672167" contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8486-433X</contrib-id><name><surname>Abbara</surname><given-names>Salam</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-41233426" contrib-type="author"><name><surname>Seror</surname><given-names>Raphaele</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib id="author-70672359" contrib-type="author"><name><surname>Henry</surname><given-names>Julien</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-70672375" contrib-type="author"><name><surname>Chretien</surname><given-names>Pascale</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib id="author-60782454" contrib-type="author"><name><surname>Gleizes</surname><given-names>Aude</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib id="author-60784145" contrib-type="author"><name><surname>Hacein-Bey-Abina</surname><given-names>Salima</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib id="author-60784224" contrib-type="author"><name><surname>Mariette</surname><given-names>Xavier</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib id="author-70672399" contrib-type="author" corresp="yes"><name><surname>Nocturne</surname><given-names>Gaetane</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></aff><aff id="aff2"><label>2</label><institution>INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Paris-Sud University</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></aff><aff id="aff3"><label>3</label><institution content-type="department">Department of Immunology</institution>,<institution>Hôpital Kremlin Bicêtre, Assistance Publique–Hopitaux de Paris (AP-HP)</institution>,<addr-line content-type="city">Le Kremlin-Bicêtre</addr-line>,<country>France</country></aff><aff id="aff4"><label>4</label><institution>Université Paris-Sud, INSERM UMR 996, Faculty of Pharmacy, Université Paris-Saclay</institution>,<addr-line content-type="city">Châtenay-Malabry</addr-line>,<country>France</country></aff><aff id="aff5"><label>5</label><institution>UTCBS, CNRS UMR 8258, INSERM U1022, Faculté de Pharmacie de Paris, Université Sorbonne-Paris-Cité, Université Paris- Descartes</institution>,<addr-line content-type="city">Paris</addr-line>,<country>France</country></aff><author-notes><corresp><label>Correspondence to</label> Dr Gaetane Nocturne; <email>gaetane.nocturne@aphp.fr</email></corresp><fn fn-type="other"><p>XM and GN are co-last authors.</p></fn></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>1</day><month>10</month><year>2019</year></pub-date><volume>5</volume><issue>2</issue><elocation-id>e001033</elocation-id><history><date date-type="received"><day>11</day><month>6</month><year>2019</year></date><date date-type="rev-recd"><day>04</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>08</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="rmdopen-2019-001033.pdf"></self-uri><abstract><sec><title>Objectives</title><p>To describe and compare the clinical and biological characteristics of subjects with primary Sjögren’s syndrome (pSS) with and without anti-RNP antibodies.</p></sec><sec><title>Methods</title><p>Patients fulfilling the American College of Rheumatology (ACR)/EULAR 2016 criteria for pSS and having anti-RNP antibodies, without other connective tissue disease diagnosed and no anti-dsDNA antibodies were retrieved from the database from our French National Reference Center. These patients were compared with all other patients with pSS with negative anti-Sm, anti-RNP and anti-dsDNA antibodies.</p></sec><sec><title>Results</title><p>Overall, 21 patients with pSS positive for anti-RNP antibodies and 446 negative for anti-RNP antibodies were retrieved. Anti-RNP-positive patients had a lower median age at onset of pSS symptoms (41.0 vs 50.0 years, p=0.01), a higher median EULAR Sjögren’s syndrome disease activity index at inclusion (8.0 vs 3.0, p<0.01), more frequently constitutional symptoms (14.3% vs 0.01%, p<0.01), myositis (19.0% vs 2.3%, p<0.01) and pulmonary (19.0% vs 5.7%, p=0.04) involvement. Moreover, anti-RNP-positive patients had higher median gammaglobulin levels (22.5 vs 13 g/L, p<0.01), more frequently anti-SSA antibodies (90.5% vs 67.1%, p=0.03), but less frequent lymphocytic sialadenitis with a focus score ≥1 (66.7% vs 85.5%, p=0.03). If the analysis is restricted to anti-SSA-positive patients, anti-RNP positivity is associated with the same clinicobiologic features except the pulmonary involvement.</p></sec><sec><title>Conclusion</title><p>Patients with pSS with anti-RNP antibodies displayed a more active systemic disease, with more frequent muscular and pulmonary involvement, and increased gammaglobulin level, compared with anti-RNP-negative patients.</p></sec></abstract><kwd-group><kwd>primary Sjögren’s Syndrome</kwd><kwd>antibodies</kwd><kwd>anti-RNP</kwd><kwd>myositis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Key messages</title></caption><sec><title>What is already known about this subject?</title><list list-type="bullet"><list-item><p>In primary Sjögren’s syndrome (pSS), anti-RNP auto-antibodies can be positive without another defined connective disorder.</p></list-item></list></sec><sec><title>What does this study add?</title><list list-type="bullet"><list-item><p>Anti-RNP-positive patients present more myositis (x10), pulmonary involvement (x4) and increased B cell biomarkers.</p></list-item></list></sec><sec><title>How might this impact on clinical practice?</title><list list-type="bullet"><list-item><p>pSS with positive anti-RNP should be monitored for muscular and pulmonary involvement.</p></list-item></list></sec></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p>Primary Sjögren’s syndrome (pSS) is an auto-immune disease that causes lymphocytic infiltration and dysfunction of salivary and lacrimal glands resulting in dryness. In addition to dryness, fatigue and pain are the classical symptoms of the disease. Primary Sjögren’s syndrome is characterised by a huge heterogeneity, besides patients suffering only from these invalidating but benign symptoms, at least one-third to two-third of the patients will develop systemic multiorgan involvement associated with an increased morbidity.<xref rid="R1" ref-type="bibr">1</xref> Anti-SSA antibodies are the main antibodies in pSS.<xref rid="R2" ref-type="bibr">2</xref> They are present in two-third of the patients, and among them, half have also anti-SSB antibodies.<xref rid="R1" ref-type="bibr">1</xref> Patients with pSS may have number of other antibodies including rheumatoid factor (RF), anticyclic citrullinated proteins (CCP), anti-Ku, anti-Sm and anti-RNP antibodies. Associations between some of these antibodies and specific subsets of patients have been described. Anti-CCP antibodies have been shown to be associated with articular and pulmonary involvement and a risk of developing rheumatoid arthritis (RA).<xref rid="R3" ref-type="bibr">3</xref> Anti-Ku antibodies are associated with muscular involvement.<xref rid="R4" ref-type="bibr">4</xref></p><p>Anti-RNP antibodies target proteins included in the U1 small nuclear ribonucleoproteins (snRNP) complex; their presence was described to be specific (specificity ranging from 84% to 100%) of mixed connective tissue disease (MCTD).<xref rid="R5" ref-type="bibr">5</xref> Among undifferentiated connective tissue diseases, Sharp <italic>et al</italic> first described MCTD as a connective tissue disease that combines anti-RNP antibodies with selective features of systemic lupus erythematosus (SLE), RA, polymyositis and systemic sclerosis.<xref rid="R6" ref-type="bibr">6</xref> Other authors later described that anti-RNP antibodies may be present in defined CTD, and associated with particular clinical features, like scleroderma-like features in patients with SLE.<xref rid="R7" ref-type="bibr">7</xref> In patients with pSS, whether these auto-antibodies are associated with a specific phenotype or outcome is unknown. In this study, we wanted to describe the clinical and biological characteristics of patients displaying pSS with anti-RNP antibodies.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Patient selection</title><p>Patients fulfilling the American College of Rheumatology (ACR)/EULAR 2016 criteria for pSS without other CTD diagnosis and having anti-RNP antibodies, without anti-DNA antibodies were searched in the database from the French National Reference Center for pSS in Paris-Sud University.<xref rid="R2" ref-type="bibr">2</xref> Patients fulfilling Systemic Lupus International Collaborating Clinics (SLICC) criteria for SLE (positive if ≥4) were excluded.<xref rid="R8" ref-type="bibr">8</xref> We compared these patients with all patients with pSS from the Paris-Sud cohort with negative anti-Sm, anti-RNP and anti-DNA antibodies. Paris-Sud cohort is a prospectively collected database of all patients participating in multidisciplinary sessions to assess a suspicion of pSS since 2000 in the Rheumatology Department of Paris-Sud University Hospital. All patients gave their informed consent to their data collection.</p></sec><sec id="s2-2"><title>Data collection</title><p>We had access to the complete medical files of all patients. The following data were collected: age, sex, patient history, familial history, age at onset of pSS symptoms, EULAR Sjögren’s syndrome disease activity index (ESSDAI) score at diagnosis, subjective symptoms of dry eyes and mouth, keratoconjunctivitis sicca (Schirmer’s test ≤5 mm/5 min or van Bijsterveld score ≥4 or breakup time test <10 s), objective xerostomia (unstimulated salivary flow rate ≤0.1 mL/min), parotid gland enlargement, extraglandular involvement, treatment, duration between the diagnosis and the last follow-up. Biological and immunological features were collected: antinuclear antibodies (evaluated by indirect immunofluorescence on HEp2 cells), anti-dsDNA antibodies (ELISA), anti-ENA antibodies (multiplex technique Bioplex 2200, Bio-Rad; confirmed with an immunodot assay Euroline ANA Profile 3, Euroimmun) including anti-Ro/SSA and anti-La/SSB antibodies as well as anti-Sm and anti-RNP antibodies (multiplex: purified proteins for anti-Sm, anti-SSA and anti-SSB antibodies, and recombinant for anti-RNP antibodies; immunodot: all purified proteins), RF (nephelometry), myositis and scleroderma dot-blot assay (dot EUROLINE Systemic Sclerosis Profile, Euroimmun). Results of minor salivary gland biopsies were classified according to Chisholm and Mason and focus score (FS) and were considered positive if FS ≥1.<xref rid="R9" ref-type="bibr">9</xref> For all patients, we assessed if they fulfilled the criteria of MCTD by Sharp <italic>et al</italic>, Alarcon-Segovia and Villareal and Kasukawa and Sharp.<xref rid="R6" ref-type="bibr">6 10 11</xref></p></sec><sec id="s2-3"><title>Statistical analysis</title><p>Data were expressed as median (IQR) for continuous variables and number (%) for categorical variables. Comparisons were performed using the Mann-Withney U test for continuous variables and χ<sup>2</sup> test or Fisher’s exact test for categorical variables, as appropriate. All p values were two-sided, p values <0.05 were considered as statistically significant. Statistical analyses were carried out using R software (V.3.3.2) and the online tool BiostaTGV.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3-1"><title>Characteristics of anti-RNP antibody-positive patients with pSS</title><p>At the time of the first evaluation, 21 patients (18 (85.7%) women) were anti-RNP positive and 446 (426 (95.5%) women) were anti-RNP negative (<xref rid="T1" ref-type="table">table 1</xref>). All patients fulfilled the ACR/EULAR 2016 criteria for pSS and had negative anti-DNA antibodies. Among anti-RNP-positive patients, none had a diagnosis of lupus according to the SLICC criteria, and three fulfilled previously described criteria of MCTD by Kasukawa and Sharp (including two also fulfilling criteria by Alarcon-Segovia and Villareal).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of the 21 patients with primary Sjögren’s syndrome with anti-RNP antibodies at inclusion, as compared with other patients with primary Sjögren’s syndrome from the Paris-Sud cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</td><td align="left" valign="bottom" rowspan="1" colspan="1">Primary Sjögren with anti-RNP n=21</td><td align="left" valign="bottom" rowspan="1" colspan="1">Primary Sjögren without anti-RNP (Paris-Sud cohort), n=446</td><td align="left" valign="bottom" rowspan="1" colspan="1">P value</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Number of women/men (ratio)</bold></td><td align="left" valign="top" rowspan="1" colspan="1">18/3 (6)</td><td align="left" valign="top" rowspan="1" colspan="1">426/20 (21.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0958</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Classification</bold></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"> </td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Subjective xerostomia or xerophthalmia</td><td align="left" valign="top" rowspan="1" colspan="1">21 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">442/446 (99.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Objective xerostomia or xerophthalmia</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>15/16 (93.8)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>418/446 (93.7)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>1</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Lymphocytic sialadenitis (focus scor</bold>e ≥<bold>1)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>14 (66.7)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>365/427 (85.5)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0293</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Median Chisholm score</td><td align="left" valign="top" rowspan="1" colspan="1">4.0 (2.0–4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3.0 (3.0–4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.8503</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Positive anti-SSA antibodies</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>19 (90.5)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>298/444 (67.1)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0288</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive anti-SSB antibodies</td><td align="left" valign="top" rowspan="1" colspan="1">5 (23.8)</td><td align="left" valign="top" rowspan="1" colspan="1">166/442 (37.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.2022</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive ACR/EULAR 2016 SGS criteria</td><td align="left" valign="top" rowspan="1" colspan="1">21 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">446 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive anti-DNA antibodies</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive anti-Sm antibodies</td><td align="left" valign="top" rowspan="1" colspan="1">6 (28.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive anti-RNP antibodies</td><td align="left" valign="top" rowspan="1" colspan="1">21 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive MCTD criteria at inclusion</td><td align="left" valign="top" rowspan="1" colspan="1">3 (14.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Sharp <italic>et al</italic></td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Kasukawa and Sharp</td><td align="left" valign="top" rowspan="1" colspan="1">3 (14.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Alarcon-Segovia and Villareal</td><td align="left" valign="top" rowspan="1" colspan="1">2 (9.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Age at onset of Sjögren’s symptoms</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>41.0</bold> (<bold>28.0–48.0)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>500</bold> (<bold>36.0–62.0)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0123</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>ESSDAI at inclusion</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>8.0 (5.0–17.0)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>3.0</bold> (<bold>1.0–6.0)</bold><bold>*</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold><</bold><bold>0.0001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Systemic manifestations</bold></td><td align="left" valign="top" rowspan="1" colspan="1"> </td><td align="left" valign="top" rowspan="1" colspan="1"> </td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Constitutional symptoms</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>3 (14.3)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>2/361 (0.01)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0013</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Parotid gland involvement</td><td align="left" valign="top" rowspan="1" colspan="1">6 (28.6)</td><td align="left" valign="top" rowspan="1" colspan="1">170/438 (38.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3457</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Joint involvement</td><td align="left" valign="top" rowspan="1" colspan="1">18 (85.7)</td><td align="left" valign="top" rowspan="1" colspan="1">335/444 (75.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4329</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Arthralgia</td><td align="left" valign="top" rowspan="1" colspan="1">18 (85.7)</td><td align="left" valign="top" rowspan="1" colspan="1">320/441 (72.6)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Non-erosive arthritis</td><td align="left" valign="top" rowspan="1" colspan="1">4 (19.0)</td><td align="left" valign="top" rowspan="1" colspan="1">48/438 (11.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Myalgia</td><td align="left" valign="top" rowspan="1" colspan="1">5 (23.8)</td><td align="left" valign="top" rowspan="1" colspan="1">132/438 (30.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5359</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Myositis</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>4 (19.0)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>10/436 (2.3)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0025</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Pulmonary interstitial lung disease</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>4 (19.0)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>25/437 (5.7)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0366</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> NSIP with altered lung diffusion, normal TLC</td><td align="left" valign="top" rowspan="1" colspan="1">2 (9.5)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> USIP with altered lung diffusion, decreased TLC</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Ground glass opacities and bronchectasis</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Cutaneous involvement</td><td align="left" valign="top" rowspan="1" colspan="1">4 (19.0)</td><td align="left" valign="top" rowspan="1" colspan="1">161/442 (36.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1042</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Isolated sclerodactyly</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Vascular purpura</td><td align="left" valign="top" rowspan="1" colspan="1">2 (9.5)</td><td align="left" valign="top" rowspan="1" colspan="1">17/436 (3.9)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Histology showing leucocytic vasculitis</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Raynaud phenomenon</td><td align="left" valign="top" rowspan="1" colspan="1">11 (52.4)</td><td align="left" valign="top" rowspan="1" colspan="1">145/437 (33.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0698</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Peripheral nervous system involvement</td><td align="left" valign="top" rowspan="1" colspan="1">2 (9.5)</td><td align="left" valign="top" rowspan="1" colspan="1">13/419 (3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1567</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Sensitive polyneuropathy—EMG confirmed</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Trigeminal neuralgia</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Central nervous system involvement</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">5/433 (1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Renal involvement</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1/124 (0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Lymphoma</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">16/443 (3.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5514</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Treatment</bold></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"> </td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Corticosteroids</td><td align="left" valign="top" rowspan="1" colspan="1">11 (52.4)</td><td align="left" valign="top" rowspan="1" colspan="1">149/438 (34.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0845</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> NSAIDs</td><td align="left" valign="top" rowspan="1" colspan="1">4 (19.0)</td><td align="left" valign="top" rowspan="1" colspan="1">167/432 (38.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1044</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Hydroxychloroquine</td><td align="left" valign="top" rowspan="1" colspan="1">11 (52.4)</td><td align="left" valign="top" rowspan="1" colspan="1">142/436 (32.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0602</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Methotrexate</td><td align="left" valign="top" rowspan="1" colspan="1">3 (14.3)</td><td align="left" valign="top" rowspan="1" colspan="1">28/434 (6.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1650</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Cyclophosphamide</td><td align="left" valign="top" rowspan="1" colspan="1">3 (14.3)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rituximab</td><td align="left" valign="top" rowspan="1" colspan="1">3 (14.3)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Azathioprine</td><td align="left" valign="top" rowspan="1" colspan="1">2 (9.5)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Mycophenolate mofetil</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><p>Results are presented as number (%), or median (IQR).</p></fn><fn id="T1_FN2"><p>Bold values are statistically significant.</p></fn><fn id="T1_FN3"><p>*Data available for 129 patients.</p></fn><fn id="T1_FN4"><p>ACR, American College of Rheumatology; EMG, electromyogram; ESSDAI, EULAR Sjögren’s syndrome disease activity index; MCTD, mixed connective tissue disease; NA, not available; NSAIDs, non-steroidal anti-inflammatory drugs; NSIP, non-specific interstitial pneumonia; TLC, total lung capacity; USIP, usual interstitial pneumonia.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2"><title>Differences in clinical patterns among anti-RNP-positive and anti-RNP-negative patients with pSS</title><p>Anti-RNP-positive patients had a lower median age at onset of pSS symptoms of nearly 10 years (41.0 vs 50.0 years, p=0.01), a higher median ESSDAI at inclusion (8.0 vs 3.0, p<0.01), were more frequently anti-SSA positive (90.5% vs 67.1%, p=0.03), but had less frequently a lymphocytic sialadenitis with a focus score ≥1 (66.7% vs 85.5%, p=0.03) (<xref rid="T1" ref-type="table">table 1</xref>).</p><p>They had more frequently constitutional symptoms (14.3% vs 0.01%, p<0.01), myositis (19.0% vs 2.3%, p<0.01) and pulmonary involvement (19.0% vs 5.7%, p=0.04) (<xref rid="T1" ref-type="table">table 1</xref>). Four patients had a myositis proven by either MRI (n=1) or histological typical pattern (n=3), with a negative myositis dot-blot assay (<xref rid="T1" ref-type="table">table 1</xref>). Four patients had an interstitial lung disease (ILD) defined by CT scan evaluation and pulmonary function testing (<xref rid="T1" ref-type="table">table 1</xref>). The two patients with non- specific interstitial pneumonia also had a myositis and positive criteria of MCTD by Kasukawa and Sharp, dryness and positive anti-SSA or a lymphocytic sialadenitis with a focus score ≥1; both did not present any sign of CTD apart from pSS with a follow-up of 4 and 6 years. The patient with usual interstitial pneumonia had a myositis but negative MCTD criteria. For the five patients who had myositis and/or ILD, pSS was diagnosed at the same time as anti-RNP positivity.</p><p>Another patient developed inflammatory polyarthralgia with a dry mouth at the age of 28 years; his pSS was diagnosed at age 44 years with positive anti-SSA and anti-RNP antibodies, an isolated mild sclerodactyly and a Mucosa Associated Lymphoid Tissue (MALT) lymphoma. The scleroderma dot-blot assay was negative. He was the third patient with positive criteria of MCTD by Kasukawa and Sharp, and the only patient with sclerodactyly; 9 years later, on the last follow-up, he showed no other sign of overlap with scleroderma. No patient presented an erosive arthritis.</p><p>Anti-RNP antibodies positivity was associated with increased B cell biomarkers (<xref rid="T2" ref-type="table">table 2</xref>), with higher median gammaglobulins (22.5 vs 13.0 g/L, p<0.01) and IgG levels (21.4 vs 13.1 g/L, p<0.01), systematic positive ANA (100.0% vs 74.7%, p<0.01), more frequent positive anti-SSA antibodies (90.5% vs 67.1%, p=0.03) and higher median beta-2 microglobulin levels (2.8 vs 2.2 g/L, p=0.03). The frequency of cryoglobulinemia was not significantly higher (4.8% vs 1.7%, p=0.32).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Biological characteristics of patients with primary Sjogren’s syndrome according to anti-RNP positivity</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1"></td><td align="left" valign="bottom" rowspan="1" colspan="1">Primary Sjögren with anti-RNP, n=21</td><td align="left" valign="bottom" rowspan="1" colspan="1">Primary Sjögren without anti-RNP (Paris-Sud cohort), n=446</td><td align="left" valign="bottom" rowspan="1" colspan="1">P value</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Positive ANA antibodies</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>21 (100.0)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>328/439 (74.7)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0035</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Positive RF</td><td align="left" valign="top" rowspan="1" colspan="1">10 (47.6)</td><td align="left" valign="top" rowspan="1" colspan="1">205/436 (47.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.9570</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anaemia*</td><td align="left" valign="top" rowspan="1" colspan="1">3 (14.3)</td><td align="left" valign="top" rowspan="1" colspan="1">63/430 (14.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thrombopenia*</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4/429 (0.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neutropenia*</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3/433 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lymphopenia*</td><td align="left" valign="top" rowspan="1" colspan="1">5 (23.8)</td><td align="left" valign="top" rowspan="1" colspan="1">57/433 (13.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1866</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Gammaglobulins or IgG >16</bold> <bold>g/L</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>16 (76.2)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>154/438 (35.2)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cryoglobulinemia</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">7/423 (1.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3235</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Low C4†</td><td align="left" valign="top" rowspan="1" colspan="1">7 (33.3)</td><td align="left" valign="top" rowspan="1" colspan="1">88/406 (21.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.2781</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Increased CK*</td><td align="left" valign="top" rowspan="1" colspan="1">4/13 (30.8)</td><td align="left" valign="top" rowspan="1" colspan="1">3/25 (12.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.2025</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Median ANA value</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>1/1280</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>1/640</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0369</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Median gammaglobulins, g/L</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>22.5 (</bold><bold>16.5–30.0</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1"><bold>13.0 (</bold><bold>10.1–16.3)</bold><bold>/422</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold><</bold><bold>0.0001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Median IgG, g/L</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>21.4 (</bold><bold>15.5–32.3</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1"><bold>13.1 (</bold><bold>9.9–16.9)</bold><bold>/409</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0005</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Median beta-2 microglobulin, mg/L</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>2.8 (</bold><bold>2.3–4.3</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1"><bold>2.2 (</bold><bold>1.7–2.7)</bold><bold>/384</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0321</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median C4 value, g/L</td><td align="left" valign="top" rowspan="1" colspan="1">0.18 (0.14–0.22)</td><td align="left" valign="top" rowspan="1" colspan="1">0.21 (0.16–0.26)/406</td><td align="left" valign="top" rowspan="1" colspan="1">0.1054</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median CK value, U/L</td><td align="left" valign="top" rowspan="1" colspan="1">119.0 (80.0–508.0)</td><td align="left" valign="top" rowspan="1" colspan="1">81.0 (57.0–125.0)/25</td><td align="left" valign="top" rowspan="1" colspan="1">0.1029</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1"><p>Results are presented as number (%), or median (IQR).</p></fn><fn id="T2_FN2"><p>Bold values are statistically significant.</p></fn><fn id="T2_FN3"><p>*Normal CK value <170 U/L, lymphocytes count <1.0 G/L, Hb level <12 g/dL, neutrophils count <1.0 G/L, platelet count <100 G/L.</p></fn><fn id="T2_FN4"><p>†C4 value≤0.15 g/L.</p></fn><fn id="T2_FN5"><p>ANA, antinuclear antibodies; CK, creatine kinase; EMG, electromyogram; Hb, haemoglobin; RF, rheumatoid factor.</p></fn></table-wrap-foot></table-wrap><p>Regarding treatments, patients with anti-RNP antibodies tended to receive more frequently corticosteroids (52.4% vs 34.0%, p=0.08), hydroxychloroquine (52.4% vs 32.6%, p=0.06) and methotrexate (14.3% vs 6.5%, p=0.17), but less frequently non-steroidal anti-inflammatory drugs (19.0% vs 38.7%, p=0.10); none of these tendencies was statistically significant.</p><p>When focusing only on patients with anti-SSA+ and comparing patients with and without anti-RNP, we confirmed that anti-RNP positivity in patients with pSS was associated with younger age, a more active disease as assessed by ESSDAI, higher frequency of constitutional symptoms, muscular involvement and higher level of gammaglobulins (<xref rid="T3" ref-type="table">table 3</xref>). However, the higher frequency of pulmonary involvement was still observed numerically (n=3/19 (15.8%) vs n=20/290 (6.9%)) but was no more statistically significant (p=0.16).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Characteristics of the 19 patients with primary Sjögren’s syndrome with anti-RNP and anti-SSA antibodies at inclusion, as compared with others patients with primary Sjögren’s syndrome from the Paris-Sud cohort with anti-SSA antibodies</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</td><td align="left" valign="bottom" rowspan="1" colspan="1">Primary Sjögren with anti-RNP and anti-SSA, n=19</td><td align="left" valign="bottom" rowspan="1" colspan="1">Primary Sjögren without anti-RNP (Paris-Sud cohort), n=297</td><td align="left" valign="bottom" rowspan="1" colspan="1">P value</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Number of women/men (ratio)</bold></td><td align="left" valign="top" rowspan="1" colspan="1">16/3 (5.3)</td><td align="left" valign="top" rowspan="1" colspan="1">284/13 (21.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0627</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Classification</bold></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"> </td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Subjective xerostomia or xerophthalmia</td><td align="left" valign="top" rowspan="1" colspan="1">19 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">293/297 (98.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Objective xerostomia or xerophthalmia</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>13/14 (92.9)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>260/286 (90.9)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>1</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Lymphocytic sialadenitis (focus score ≥1)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (63.2)</td><td align="left" valign="top" rowspan="1" colspan="1">222/279 (79.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1429</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Median Chisholm score</td><td align="left" valign="top" rowspan="1" colspan="1">3.5 (2.0–4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3.0 (3.0–4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.6078</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive anti-SSA antibodies</td><td align="left" valign="top" rowspan="1" colspan="1">19 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">298/298 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Positive anti-SSB antibodies</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>5 (26.3)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>161/295 (54.6)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0186</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive anti-Sm antibodies</td><td align="left" valign="top" rowspan="1" colspan="1">5 (26.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive anti-RNP antibodies</td><td align="left" valign="top" rowspan="1" colspan="1">19 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive MCTD criteria at inclusion</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Sharp <italic>et al</italic></td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Kasukawa and Sharp</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Alarcon-Segovia and Villareal</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Age at onset of Sjögren’s symptoms</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>41.0</bold> (<bold>27.5–47.5</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1"><bold>49.0</bold> (<bold>36.5–61.0</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0173</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>ESSDAI at inclusion</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>8.0</bold> (<bold>5.5–16.5</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1"><bold>3.0</bold> (<bold>1.0–7.0)</bold><bold>/89</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold><</bold><bold>0.0001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Systemic manifestations</bold></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"> </td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Constitutional symptoms</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>3 (15.8)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>1/278 (0.004)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0009</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Parotid gland involvement</td><td align="left" valign="top" rowspan="1" colspan="1">6 (31.6)</td><td align="left" valign="top" rowspan="1" colspan="1">136/293 (46.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.2082</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Joint involvement</td><td align="left" valign="top" rowspan="1" colspan="1">17 (89.5)</td><td align="left" valign="top" rowspan="1" colspan="1">211/293 (72.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1142</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Myalgia</td><td align="left" valign="top" rowspan="1" colspan="1">4 (21.1)</td><td align="left" valign="top" rowspan="1" colspan="1">91/290 (31.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4464</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Myositis</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>3 (15.8)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>8/288 (2.8)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0243</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Myalgia, 1N</td> <td align="left" valign="top" rowspan="1" colspan="1">1 (5.3)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Myalgia, CK≥6N</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Myositis on the MRI</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.3)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Histological confirmation</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">–</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Pulmonary interstitial lung disease</td><td align="left" valign="top" rowspan="1" colspan="1">3 (15.8)</td><td align="left" valign="top" rowspan="1" colspan="1">20/290 (6.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1589</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Cutaneous involvement</td><td align="left" valign="top" rowspan="1" colspan="1">4 (21.1)</td><td align="left" valign="top" rowspan="1" colspan="1">28/288 (9.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1224</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Raynaud phenomenon</td><td align="left" valign="top" rowspan="1" colspan="1">9 (47.4)</td><td align="left" valign="top" rowspan="1" colspan="1">98/291 (33.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.2239</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Peripheral nervous system involvement</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">8/283 (2.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1248</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Lymphoma</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.3)</td><td align="left" valign="top" rowspan="1" colspan="1">13/294 (4.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5918</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Treatment</bold></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"> </td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Corticosteroids</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>9 (47.4)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>45/288 (15.6)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0019</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> NSAIDs</td><td align="left" valign="top" rowspan="1" colspan="1">4 (21.1)</td><td align="left" valign="top" rowspan="1" colspan="1">59/286 (20.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Hydroxychloroquine</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>11 (57.9)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>62/288 (21.5)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0010</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Methotrexate</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">9/288 (3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1429</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Biology</bold></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"> </td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive ANA antibodies</td><td align="left" valign="top" rowspan="1" colspan="1">19 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">250/292 (85.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0877</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive RF</td><td align="left" valign="top" rowspan="1" colspan="1">10 (52.6)</td><td align="left" valign="top" rowspan="1" colspan="1">177/290 (61.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4679</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Lymphopenia *</td><td align="left" valign="top" rowspan="1" colspan="1">4 (21.1)</td><td align="left" valign="top" rowspan="1" colspan="1">38/287 (13.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3098</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Gammaglobulins or IgG >16</bold> <bold>g/L</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>15 (78.9)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>152/291 (52.2)</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0310</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Cryoglobulinemia</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">4/281 (1.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.2807</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Low C4†</td><td align="left" valign="top" rowspan="1" colspan="1">6 (31.6)</td><td align="left" valign="top" rowspan="1" colspan="1">69/269 (2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5916</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Increased CK*</td><td align="left" valign="top" rowspan="1" colspan="1">3/13 (23.1)</td><td align="left" valign="top" rowspan="1" colspan="1">2/15 (13.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.6389</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Median ANA value</td><td align="left" valign="top" rowspan="1" colspan="1">1/1280</td><td align="left" valign="top" rowspan="1" colspan="1">1/1280</td><td align="left" valign="top" rowspan="1" colspan="1">0.5304</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Median gammaglobulins, g/L</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>24.0</bold> (<bold>16.5–30.95</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1"><bold>14.0 (12.75–16.25)</bold><bold>/40</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0013</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> <bold>Median IgG, g/L</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>21.4</bold> (<bold>16.5–32.6</bold>)</td><td align="left" valign="top" rowspan="1" colspan="1"><bold>14.8</bold> (<bold>11.7–18.9)</bold><bold>/172</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.0057</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Median beta-2 microglobulin, mg/L</td><td align="left" valign="top" rowspan="1" colspan="1">2.9 (2.2–4.4)</td><td align="left" valign="top" rowspan="1" colspan="1">2.4 (1.9–3.0)/259</td><td align="left" valign="top" rowspan="1" colspan="1">0.1377</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Median C4 value, g/L</td><td align="left" valign="top" rowspan="1" colspan="1">0.18 (0.14–0.22)</td><td align="left" valign="top" rowspan="1" colspan="1">0.20 (0.15–0.25)/269</td><td align="left" valign="top" rowspan="1" colspan="1">0.2230</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Median CK value, U/L</td><td align="left" valign="top" rowspan="1" colspan="1">103.0 (77.5–272.5)</td><td align="left" valign="top" rowspan="1" colspan="1">72.0 (50.0–84.8)/16</td><td align="left" valign="top" rowspan="1" colspan="1">0.0992</td></tr></tbody></table><table-wrap-foot><fn id="T3_FN1"><p>Results are presented as number (%), or median (IQR).</p></fn><fn id="T3_FN2"><p>Bold values are statistically significant.</p></fn><fn id="T3_FN3"><p>*Normal CK value <170 U/L, lymphocytes count <1.0 G/L.</p></fn><fn id="T3_FN4"><p>†C4 value≤0.15 g/L.</p></fn><fn id="T3_FN5"><p>ANA, antinuclear antibodies; CK, creatine kinase; EMG, electromyogram;ESSDAI, EULAR Sjögren’s syndrome disease activity index; MCTD, mixed connective tissue disease; NA, not available;NSAIDs, non-steroidal anti-inflammatory drugs;RF, rheumatoid factor.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-3"><title>Outcome and follow-up</title><p>After a median follow-up of 5 years (IQR 1–15 years), none of the anti-RNP-positive patients developed a defined CTD. Moreover, the 18 patients with negative MCTD criteria but positive anti-RNP antibodies did not present positive criteria of MCTD during follow-up.</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Our study is the first to focus on the specific characteristics of patients with defined pSS associated with anti-RNP antibodies. When comparing 21 patients with pSS with anti-RNP with 446 patients with pSS without anti-RNP antibodies, we found that the positivity of anti-RNP antibodies was associated with a more active systemic disease as assessed by ESSDAI, particularly with a higher prevalence of some specific organ involvements including myositis (10 times more) and pulmonary involvement (4 times more), and an increase in B cell biomarker levels</p><p>Of note, patients with anti-RNP antibodies were also more frequently anti-SSA positive, a feature that has previously been shown to be associated with a higher prevalence of systemic manifestations.<xref rid="R12" ref-type="bibr">12</xref> However, in our study, when focusing only on patients with pSS with anti-SSA+ only, anti-RNP positivity was still associated with a more active disease and the same specific phenotype demonstrating that anti-RNP and not a higher frequency of anti-SSA was associated with this specific phenotype.</p><p>Whether the association between pSS with anti-RNP antibodies and a more active disease is supported by physiopathology or is linked to a differential response to treatments deserves further studies. Implication of toll-like receptor (TLR) 7 has been suggested for patients with pSS, SLE and MCTD, suggesting that they could share a common pathway.<xref rid="R13" ref-type="bibr">13–15</xref> Actually, nucleic acid contained in RNP can link to TLRs and stimulate their signalling. The involvement of TLR 8 and 9, which is observed in patients with MCTD, is still debated in patients with pSS.<xref rid="R14" ref-type="bibr">14 15</xref></p><p>Among our anti-RNP-positive patients, 28.6% had anti-Sm antibodies but none fulfilled criteria for SLE or developed an SLE with a median follow-up of 5 years. Anti-Sm antibodies target proteins that bind the small uridine-rich nuclear ribonucleic acids U1, U2, U4 and U5 in the cytoplasm to form snRNP in the nucleus, which explains why they are found in association with anti-RNP.<xref rid="R5" ref-type="bibr">5</xref></p><p>Despite having positive anti-RNP antibodies, all patients fulfilled criteria for pSS with authentic typical Sjögren’s symptoms associated with typical features and no diagnosis of another CTD with a median follow-up of 5 years (IQR 1–15 years). A minority of patients fulfilled criteria for MCTD (n=3, 14.3%), but none presented enough clinical and biological features to suggest an overlap with another CTD with a median follow-up of 5 years.</p><p>Overall, our results confirm that the presence of anti-RNP antibodies is associated with certain clinical associations. In patients with pSS, these results support the need for a specific monitoring of muscular and pulmonary involvement in case of anti-RNP positivity in patients with pSS.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Contributors:</bold> All the authors contributed to the manuscript, conception and design, collection of data, analysis and interpretation. All the authors reviewed the final version of the manuscript.</p></fn><fn fn-type="other"><p><bold>Funding:</bold> The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.</p></fn><fn fn-type="COI-statement"><p><bold>Competing interests:</bold> None declared.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not required.</p></fn><fn fn-type="other"><p><bold>Ethics approval:</bold> The data collection was approved by the local ethics committee.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Data availability statement:</bold> Data are available on reasonable request.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos-Casals</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brito-Zerón</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Seror</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group><article-title>Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task force recommendations for articular, cutaneous, pulmonary and renal involvements</article-title>. <source>Rheumatology</source><year>2015</year>;<volume>54</volume>:<fpage>30</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/kev200</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiboski</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Shiboski</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Seror</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group><article-title>2016 American College of Rheumatology/European League against rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts</article-title>. <source>Arthritis Rheumatol</source><year>2017</year>;<volume>69</volume>:<fpage>35</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1002/art.39859</pub-id><pub-id pub-id-type="pmid">27785888</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Payet</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Belkhir</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gottenberg</surname><given-names>JE</given-names></name>, <etal>et al</etal></person-group><article-title>Acpa-Positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?</article-title><source>RMD Open</source><year>2015</year>;<volume>1</volume>:<elocation-id>e000066</elocation-id><pub-id pub-id-type="doi">10.1136/rmdopen-2015-000066</pub-id><pub-id pub-id-type="pmid">26509066</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavazzana</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Ceribelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Quinzanini</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group><article-title>Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases</article-title>. <source>Lupus</source><year>2008</year>;<volume>17</volume>:<fpage>727</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1177/0961203308089442</pub-id><pub-id pub-id-type="pmid">18625650</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benito-Garcia</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Schur</surname><given-names>PH</given-names></name>, <name name-style="western"><surname>Lahita</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group><article-title>Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests</article-title>. <source>Arthritis Care Res</source><year>2004</year>;<volume>51</volume>:<fpage>1030</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1002/art.20836</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharp</surname><given-names>GC</given-names></name>, <name name-style="western"><surname>Irvin</surname><given-names>WS</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>EM</given-names></name>, <etal>et al</etal></person-group><article-title>Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)</article-title>. <source>Am J Med</source><year>1972</year>;<volume>52</volume>:<fpage>148</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/0002-9343(72)90064-2</pub-id><pub-id pub-id-type="pmid">4621694</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>ter Borg</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Groen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Horst</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group><article-title>Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus</article-title>. <source>Semin Arthritis Rheum</source><year>1990</year>;<volume>20</volume>:<fpage>164</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/0049-0172(90)90057-M</pub-id><pub-id pub-id-type="pmid">2287941</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petri</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Orbai</surname><given-names>A-M</given-names></name>, <name name-style="western"><surname>Alarcón</surname><given-names>GS</given-names></name>, <etal>et al</etal></person-group><article-title>Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source><year>2012</year>;<volume>64</volume>:<fpage>2677</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1002/art.34473</pub-id><pub-id pub-id-type="pmid">22553077</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chisholm</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Mason</surname><given-names>DK</given-names></name></person-group><article-title>Labial salivary gland biopsy in Sjögren's disease</article-title>. <source>J Clin Pathol</source><year>1968</year>;<volume>21</volume>:<fpage>656</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1136/jcp.21.5.656</pub-id><pub-id pub-id-type="pmid">5697370</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Alarcon-Segovia</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Villareal</surname><given-names>M</given-names></name></person-group><chapter-title>Classification and diagnosis criteria for mixed connective tissue disease</chapter-title> : <person-group person-group-type="editor"><name name-style="western"><surname>Kasukawa</surname><given-names>R</given-names></name>, <name name-style="western"><surname>sharp</surname><given-names>G</given-names></name></person-group>, <source>Mixed connective tissue disease and antinuclear antibodies</source>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier Science</publisher-name>, <year>1987</year>: <fpage>33</fpage>–<lpage>40</lpage>.</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kasukawa</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sharp</surname><given-names>G</given-names></name></person-group><source>Mixed connective tissue disease and antinuclear antibodies</source>. <volume>357</volume><publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier Science</publisher-name>, <year>1987</year>.</mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bournia</surname><given-names>V-K</given-names></name>, <name name-style="western"><surname>Vlachoyiannopoulos</surname><given-names>PG</given-names></name></person-group><article-title>Subgroups of Sjögren syndrome patients according to serological profiles</article-title>. <source>J Autoimmun</source><year>2012</year>;<volume>39</volume>:<fpage>15</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2012.03.001</pub-id><pub-id pub-id-type="pmid">22575069</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paradowska-Gorycka</surname><given-names>A</given-names></name></person-group><article-title>Review papers U1-RNP and Toll-like receptors in the pathogenesis of mixed connective tissue disease Part II. endosomal TLRs and their biological significance in the pathogenesis of mixed connective tissue disease</article-title>. <source>Reumatologia/Rheumatology</source><year>2015</year>;<volume>3</volume>:<fpage>143</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.5114/reum.2015.53136</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karlsen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jakobsen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Jonsson</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group><article-title>Expression of Toll-like receptors in peripheral blood mononuclear cells of patients with primary Sjögren's syndrome</article-title>. <source>Scand J Immunol</source><year>2017</year>;<volume>85</volume>:<fpage>220</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/sji.12520</pub-id><pub-id pub-id-type="pmid">27943374</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goules</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Kapsogeorgou</surname><given-names>EK</given-names></name>, <name name-style="western"><surname>Tzioufas</surname><given-names>AG</given-names></name></person-group><article-title>Insight into pathogenesis of Sjögren's syndrome: dissection on autoimmune infiltrates and epithelial cells</article-title>. <source>Clin Immunol</source><year>2017</year>;<volume>182</volume>:<fpage>30</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2017.03.007</pub-id><pub-id pub-id-type="pmid">28330683</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000796 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000796 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:6802987
|texte= Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:31673417" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |